Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D30EZF
|
|||
| Drug Name |
Zilebesiran
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Company |
Alnylam Pharmaceuticals Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensinogen messenger RNA (AGT mRNA) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05103332) A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.